항체 수탁 제조 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 제품별, 유래별, 치료 영역별, 최종 사용자별, 지역별 시장 예측(2025-2034년)

The antibody contract manufacturing market size is expected to reach USD 44.96 billion by 2034, according to a new study by Polaris Market Research. The report "Antibody Contract Manufacturing Market Share, Size, Trends, Industry Analysis Report: By Product (Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Others), By Source, By Therapeutic Area, By End User, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Antibody contract manufacturing involves the outsourced production of monoclonal antibodies, polyclonal, and bispecific antibodies, enabling biopharmaceutical companies to meet growing therapeutic and diagnostic demands. These services are executed under stringent regulatory and quality guidelines to ensure high yield, product consistency and clinical-grade safety.

The market growth is fueled by the increasing global incidence of cancer and other chronic diseases, which is driving demand for targeted antibody-based therapies. Rising global R&D expenditure in oncology and immunology is further boosting the development of next-generation biologics.

Antibody Contract Manufacturing Market Report Highlights

Based on product, the monoclonal antibodies segment accounted for the largest market share in 2024, due to the rising number of kidney, liver, and heart transplant surgeries requiring long-term immunosuppressive therapy.

Based on source, the mammalian segment dominated the market, driven by its high compatibility with complex protein structures and ability to produce glycosylation profiles essential for therapeutic efficacy.

Based on therapeutic area, the infectious diseases segment is expected to witness the fastest growth, fueled by increasing demand for antibody-based therapies to combat emerging viral infections and rising prevalence of chronic infectious conditions.

Based on end user, the biopharmaceutical companies segment held the dominant share in 2024, due to the growing trend of outsourcing antibody production to specialized CMOs for cost optimization and faster commercialization.

North America dominated the global antibody contract manufacturing market in 2024, fueled by robust biopharmaceutical manufacturing capacity and the rapid integration of advanced biologics into production processes.

Asia Pacific witnessed a steady growth, due to significant growth in the regional biotechnology industry, coupled with rising collaborations and outsourcing agreements with international pharmaceutical companies.

A few global key market players include Lonza Group AG, Samsung Biologics, WuXi Biologics, Boehringer Ingelheim International GmbH, Fujifilm Diosynth Biotechnologies, Catalent, Inc., AbbVie Inc., Thermo Fisher Scientific Inc., Shilpa Medicare Ltd., Lotte Biologics, Merck Group, and Charles River Laboratories.

Polaris Market Research has segmented the market report on the basis of product, source, therapeutic area, end user, and region:

By Product Outlook (Revenue, USD Billion, 2020-2034)

Monoclonal Antibodies

Polyclonal Antibodies

Bispecific Antibodies

Others

By Source Outlook (Revenue, USD Billion, 2020-2034)

Mammalian

Microbial

By Therapeutic Area (Revenue, USD Billion, 2020-2034)

Oncology

Neurology

Cardiology

Infectious Diseases

Other Therapeutic Areas

By End User (Revenue, USD Billion, 2020-2034)

Biopharmaceutical Companies

Research Laboratories

Others

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Antibody Contract Manufacturing Market Insights

• 4.1. Antibody Contract Manufacturing Market - Market Snapshot
• 4.2. Antibody Contract Manufacturing Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing Cases of Cancer Worldwide
    • 4.2.1.2. Rising Global R&D Expenditure
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. High Manufacturing Cost and Complex Regulatory Compliance
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Antibody Contract Manufacturing Market Trends
• 4.6. Value Chain Analysis

5. Global Antibody Contract Manufacturing Market, by Product

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• 5.3. Monoclonal Antibodies
  • 5.3.1. Global Antibody Contract Manufacturing Market, by Monoclonal Antibodies, by Region, 2020-2034 (USD Billion)
• 5.4. Polyclonal Antibodies
  • 5.4.1. Global Antibody Contract Manufacturing Market, by Polyclonal Antibodies, by Region, 2020-2034 (USD Billion)
• 5.5. Bispecific Antibodies
  • 5.5.1. Global Antibody Contract Manufacturing Market, by Bispecific Antibodies, by Region, 2020-2034 (USD Billion)
• 5.6. Others
  • 5.6.1. Global Antibody Contract Manufacturing Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Antibody Contract Manufacturing Market, by Source

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• 6.3. Mammalian
  • 6.3.1. Global Antibody Contract Manufacturing Market, by Mammalian, by Region, 2020-2034 (USD Billion)
• 6.4. Microbial
  • 6.4.1. Global Antibody Contract Manufacturing Market, by Microbial, by Region, 2020-2034 (USD Billion)

7. Global Antibody Contract Manufacturing Market, by Therapeutic Area

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• 7.3. Oncology
  • 7.3.1. Global Antibody Contract Manufacturing Market, by Oncology, by Region, 2020-2034 (USD Billion)
• 7.4. Neurology
  • 7.4.1. Global Antibody Contract Manufacturing Market, by Neurology, by Region, 2020-2034 (USD Billion)
• 7.5. Cardiology
  • 7.5.1. Global Antibody Contract Manufacturing Market, by Cardiology, by Region, 2020-2034 (USD Billion)
• 7.6. Infectious Diseases
  • 7.6.1. Global Antibody Contract Manufacturing Market, by Infectious Diseases, by Region, 2020-2034 (USD Billion)
• 7.7. Other Therapeutic Areas
  • 7.7.1. Global Antibody Contract Manufacturing Market, by Other Therapeutic Areas, by Region, 2020-2034 (USD Billion)

8. Global Antibody Contract Manufacturing Market, by End User

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Global Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• 8.3. Biopharmaceutical Companies
  • 8.3.1. Global Antibody Contract Manufacturing Market, by Biopharmaceutical Companies by Region, 2020-2034 (USD Billion)
• 8.4. Research Laboratories
  • 8.4.1. Global Antibody Contract Manufacturing Market, by Research Laboratories, by Region, 2020-2034 (USD Billion)
• 8.5. Others
  • 8.5.1. Global Antibody Contract Manufacturing Market, by Others, by Region, 2020-2034 (USD Billion)

9. Global Antibody Contract Manufacturing Market, by Geography

• 9.1. Key Findings
• 9.2. Introduction
  • 9.2.1. Antibody Contract Manufacturing Market Assessment, By Geography, 2020-2034 (USD Billion)
• 9.3. Antibody Contract Manufacturing Market - North America
  • 9.3.1. North America: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
  • 9.3.2. North America: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
  • 9.3.3. North America: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
  • 9.3.4. North America: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.3.5. Antibody Contract Manufacturing Market - U.S.
    • 9.3.5.1. U.S.: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.3.5.2. U.S.: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.3.5.3. U.S.: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.3.5.4. U.S.: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.3.6. Antibody Contract Manufacturing Market - Canada
    • 9.3.6.1. Canada: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.3.6.2. Canada: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.3.6.3. Canada: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.3.6.4. Canada: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• 9.4. Antibody Contract Manufacturing Market - Europe
  • 9.4.1. Europe: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
  • 9.4.2. Europe: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
  • 9.4.3. Europe: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
  • 9.4.4. Europe: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.5. Antibody Contract Manufacturing Market - UK
    • 9.4.5.1. UK: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.5.2. UK: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.5.3. UK: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.5.4. UK: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.6. Antibody Contract Manufacturing Market - France
    • 9.4.6.1. France: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.6.2. France: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.6.3. France: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.6.4. France: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.7. Antibody Contract Manufacturing Market - Germany
    • 9.4.7.1. Germany: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.7.2. Germany: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.7.3. Germany: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.7.4. Germany: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.8. Antibody Contract Manufacturing Market - Italy
    • 9.4.8.1. Italy: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.8.2. Italy: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.8.3. Italy: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.8.4. Italy: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.9. Antibody Contract Manufacturing Market - Spain
    • 9.4.9.1. Spain: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.9.2. Spain: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.9.3. Spain: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.9.4. Spain: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.10. Antibody Contract Manufacturing Market - Netherlands
    • 9.4.10.1. Netherlands: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.10.2. Netherlands: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.10.3. Netherlands: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.10.4. Netherlands: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.11. Antibody Contract Manufacturing Market - Russia
    • 9.4.11.1. Russia: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.11.2. Russia: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.11.3. Russia: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.11.4. Russia: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.12. Antibody Contract Manufacturing Market - Rest of Europe
    • 9.4.12.1. Rest of Europe: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.12.2. Rest of Europe: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.12.3. Rest of Europe: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.12.4. Rest of Europe: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• 9.5. Antibody Contract Manufacturing Market - Asia Pacific
  • 9.5.1. Asia Pacific: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
  • 9.5.2. Asia Pacific: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
  • 9.5.3. Asia Pacific: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
  • 9.5.4. Asia Pacific: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.5. Antibody Contract Manufacturing Market - China
    • 9.5.5.1. China: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.5.2. China: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.5.3. China: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.5.4. China: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.6. Antibody Contract Manufacturing Market - India
    • 9.5.6.1. India: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.6.2. India: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.6.3. India: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.6.4. India: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.7. Antibody Contract Manufacturing Market - Malaysia
    • 9.5.7.1. Malaysia: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.7.2. Malaysia: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.7.3. Malaysia: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.7.4. Malaysia: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.8. Antibody Contract Manufacturing Market - Japan
    • 9.5.8.1. Japan: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.8.2. Japan: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.8.3. Japan: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.8.4. Japan: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.9. Antibody Contract Manufacturing Market - Indonesia
    • 9.5.9.1. Indonesia: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.9.2. Indonesia: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.9.3. Indonesia: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.9.4. Indonesia: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.10. Antibody Contract Manufacturing Market - South Korea
    • 9.5.10.1. South Korea: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.10.2. South Korea: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.10.3. South Korea: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.10.4. South Korea: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.11. Antibody Contract Manufacturing Market - Australia
    • 9.5.11.1. Australia: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.11.2. Australia: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.11.3. Australia: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.11.4. Australia: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.12. Antibody Contract Manufacturing Market - Rest of Asia Pacific
    • 9.5.12.1. Rest of Asia Pacific: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.12.2. Rest of Asia Pacific: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.12.3. Rest of Asia Pacific: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.12.4. Rest of Asia Pacific: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• 9.6. Antibody Contract Manufacturing Market - Middle East & Africa
  • 9.6.1. Middle East & Africa: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
  • 9.6.2. Middle East & Africa: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
  • 9.6.3. Middle East & Africa: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
  • 9.6.4. Middle East & Africa: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.6.5. Antibody Contract Manufacturing Market - Saudi Arabia
    • 9.6.5.1. Saudi Arabia: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.6.5.2. Saudi Arabia: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.6.5.3. Saudi Arabia: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.6.5.4. Saudi Arabia: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.6.6. Antibody Contract Manufacturing Market - UAE
    • 9.6.6.1. UAE: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.6.6.2. UAE: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.6.6.3. UAE: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.6.6.4. UAE: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.6.7. Antibody Contract Manufacturing Market - Israel
    • 9.6.7.1. Israel: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.6.7.2. Israel: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.6.7.3. Israel: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.6.7.4. Israel: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.6.8. Antibody Contract Manufacturing Market - South Africa
    • 9.6.8.1. South Africa: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.6.8.2. South Africa: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.6.8.3. South Africa: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.6.8.4. South Africa: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.6.9. Antibody Contract Manufacturing Market - Rest of Middle East & Africa
    • 9.6.9.1. Rest of Middle East & Africa: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.6.9.2. Rest of Middle East & Africa: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.6.9.3. Rest of Middle East & Africa: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.6.9.4. Rest of Middle East & Africa: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• 9.7. Antibody Contract Manufacturing Market - Latin America
  • 9.7.1. Latin America: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
  • 9.7.2. Latin America: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
  • 9.7.3. Latin America: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
  • 9.7.4. Latin America: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.7.5. Antibody Contract Manufacturing Market - Mexico
    • 9.7.5.1. Mexico: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.7.5.2. Mexico: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.7.5.3. Mexico: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.7.5.4. Mexico: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.7.6. Antibody Contract Manufacturing Market - Brazil
    • 9.7.6.1. Brazil: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.7.6.2. Brazil: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.7.6.3. Brazil: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.7.6.4. Brazil: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.7.7. Antibody Contract Manufacturing Market - Argentina
    • 9.7.7.1. Argentina: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.7.7.2. Argentina: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.7.7.3. Argentina: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.7.7.4. Argentina: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.7.8. Antibody Contract Manufacturing Market - Rest of Latin America
    • 9.7.8.1. Rest of Latin America: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.7.8.2. Rest of Latin America: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.7.8.3. Rest of Latin America: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.7.8.4. Rest of Latin America: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)

10. Competitive Landscape

• 10.1. Expansion and Acquisition Analysis
  • 10.1.1. Expansion
  • 10.1.2. Acquisitions
• 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

• 11.1. AbbVie Inc.
  • 11.1.1. Company Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Benchmarking
  • 11.1.4. Recent Development
• 11.2. Boehringer Ingelheim International GmbH
  • 11.2.1. Company Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Benchmarking
  • 11.2.4. Recent Development
• 11.3. Catalent, Inc.
  • 11.3.1. Company Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Benchmarking
  • 11.3.4. Recent Development
• 11.4. Charles River Laboratories
  • 11.4.1. Company Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Benchmarking
  • 11.4.4. Recent Development
• 11.5. Fujifilm Diosynth Biotechnologies
  • 11.5.1. Company Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Benchmarking
  • 11.5.4. Recent Development
• 11.6. Lonza Group AG
  • 11.6.1. Company Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Benchmarking
  • 11.6.4. Recent Development
• 11.7. Lotte Biologics
  • 11.7.1. Company Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Benchmarking
  • 11.7.4. Recent Development
• 11.8. Merck Group
  • 11.8.1. Company Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Benchmarking
  • 11.8.4. Recent Development
• 11.9. Samsung Biologics
  • 11.9.1. Company Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Benchmarking
  • 11.9.4. Recent Development
• 11.10. Shilpa Medicare Ltd.
  • 11.10.1. Company Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Benchmarking
  • 11.10.4. Recent Development
• 11.11. Thermo Fisher Scientific Inc.
  • 11.11.1. Company Overview
  • 11.11.2. Financial Performance
  • 11.11.3. Product Benchmarking
  • 11.11.4. Recent Development
• 11.12. WuXi Biologics
  • 11.12.1. Company Overview
  • 11.12.2. Financial Performance
  • 11.12.3. Product Benchmarking
  • 11.12.4. Recent Development